Analysts predict that CryoPort Inc (NASDAQ:CYRX) will post $4.32 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for CryoPort’s earnings. The lowest sales estimate is $4.20 million and the highest is $4.52 million. CryoPort reported sales of $2.92 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 47.9%. The business is scheduled to issue its next earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that CryoPort will report full-year sales of $18.92 million for the current fiscal year, with estimates ranging from $18.39 million to $19.78 million. For the next fiscal year, analysts expect that the company will report sales of $37.03 million per share, with estimates ranging from $33.86 million to $40.30 million. Zacks’ sales calculations are an average based on a survey of analysts that follow CryoPort.
CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Thursday, May 3rd. The consumer goods maker reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03). CryoPort had a negative net margin of 66.29% and a negative return on equity of 48.12%. The company had revenue of $4.02 million for the quarter, compared to analysts’ expectations of $3.84 million. During the same period in the prior year, the firm earned ($0.10) earnings per share. The firm’s quarterly revenue was up 48.3% on a year-over-year basis.
A number of brokerages recently weighed in on CYRX. BidaskClub raised shares of CryoPort from a “hold” rating to a “buy” rating in a research report on Monday, May 14th. ValuEngine raised shares of CryoPort from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target (up from $10.00) on shares of CryoPort in a research report on Thursday, March 8th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. CryoPort presently has an average rating of “Buy” and a consensus price target of $11.63.
In related news, CEO Jerrell Shelton sold 29,257 shares of the company’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $9.83, for a total transaction of $287,596.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.60% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently modified their holdings of the business. Millennium Management LLC lifted its holdings in CryoPort by 205.0% in the 1st quarter. Millennium Management LLC now owns 434,068 shares of the consumer goods maker’s stock worth $3,733,000 after buying an additional 291,737 shares in the last quarter. Taylor Wealth Management Partners lifted its holdings in CryoPort by 5.6% in the 4th quarter. Taylor Wealth Management Partners now owns 415,575 shares of the consumer goods maker’s stock worth $3,570,000 after buying an additional 21,935 shares in the last quarter. OppenheimerFunds Inc. lifted its holdings in CryoPort by 20.6% in the 4th quarter. OppenheimerFunds Inc. now owns 406,829 shares of the consumer goods maker’s stock worth $3,495,000 after buying an additional 69,571 shares in the last quarter. Allianz Asset Management GmbH lifted its holdings in CryoPort by 240.5% in the 4th quarter. Allianz Asset Management GmbH now owns 387,099 shares of the consumer goods maker’s stock worth $3,325,000 after buying an additional 273,426 shares in the last quarter. Finally, Pier Capital LLC acquired a new position in CryoPort in the 4th quarter worth $2,916,000. Hedge funds and other institutional investors own 28.67% of the company’s stock.
Shares of CryoPort opened at $9.59 on Tuesday, according to MarketBeat. CryoPort has a 52-week low of $3.08 and a 52-week high of $10.40. The firm has a market cap of $259.74 million, a PE ratio of -28.21 and a beta of 0.71.
CryoPort Company Profile
Cryoport, Inc provides cryogenic logistics solutions to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, a dry vapor cryogenic shipper that use liquid nitrogen contained inside a vacuum insulated vessel, which serves as a refrigerant to provide stable storage temperatures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.